Replies to post #14578 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

You will note that I stated potentially become secondary or primary prevention treatment. The fact is they have 5 years of safety data and very good spring board to launch further trials involving CV risk reduction.

Aspirin, for its blood thinning capabilities is viewed as both a primary and secondary prevention treatment. Why not testosterone restoration? Especially if the connection between low testosterone and CV disease is established.

Read the Bliss trial and you can see that the FDA clearly wants to get more information on the benefits of testosterone. They have added a 5 year commitment post approval to continue to testing for safety.

What the board all realizes is that if this discovery can be proven before the FDA through additional trails, it would be huge.